Latest news

Milestone: Launch of the inPROBE production line

Next milestone on the way to implementing a pilot production of optoelectronic components for the optical biosensors used in inPROBE® microprobes. The inaugural launch of the inPROBE production line.

SDS Optic #news: Clairfield International as a transaction advisor for SDS Optic S.A. in the commercialisation of inPROBE®

SDS Optic signed a contract for advising in finding a strategic partner interested in commercialisation of the platform with the renown Clairfield International from New York.

SDS Optic #news: clinical trials and pilot production run of the inPROBE microprobe

We witnessed several really intense months. Our team was working hard on the implementation of Phase I of clinical trials. Engineers are taken up by the pilot production of the inPROBE microprobe. QA specialists ensure the correct implementation of the ISO system and MDR requirements. Read the complete article to find out what else was (and is) going on in our Company.

SDS Optic #news: inPROBE as the Polish Product of the Future and launching of the Clean Room

We have already done a lot of work and preparations for clinical trials, launching Clean Room rooms and equipment for own production of inPROBE biosensor fibre optic elements, and we also took part in international conferences and industry events. SDS Optic also received a unique distinction. We have a fair dose of news for you from the first half of 2022.

Summary of 2021 at SDS Optic Inc.
and the announcement of the next milestones in 2022

The past months have been accompanied by many milestone events for the development of the company and its product. SDS Optic S.A., a company developing the proprietary inPROBE technology platform for real-time medical diagnosis of cancer, infectious, viral, bacterial and fungal diseases, has published its annual report for 2021. Find out more about our company's life.

Urządzenie inPROBE - wizja SDS Optic S.A.OUR VISION

According to GLOBOCAN 2020 data, over 2 mln breast cancer cases yearly are noticed worldwide. At the same time, breast cancer took the lives of almost 700 thousand people.

Medical science believe that effective and fast detection of the illness would save the lives of many patients around the world. That’s why we created and developed the inPROBE medical device, first ever optic fibre microprobe, enabling in vivo real-time breast cancer diagnosis.

Our vision to “increase the cancer cure rate by 30% by 2030” is an indissoluble part of our DNA – connecting and motivating the whole SDS Optic team.

Who we are

The SDS Optic team is working on a breakthrough technology based on rapid detection of test substances in the body, including cancer markers, with particular accuracy, the using laser beams and innovative components. At the end of the process, the reading is interpreted on the detector by means of an appropriate conversion algorithm, which gives the level of the compound tested (e.g. HER2 cancer marker) in numerical form. 

Our technology is a breakthrough. We create inPROBE a tool for direct measurement of the HER2 marker. The use of a microsonde will save the patient pain and stress associated with a biopsy and waiting for the result. We want to save up to 30% of people diagnosed with cancer by 2030

Our partners